Chat with us, powered by LiveChat

Loading...

Cytotoxic Drugs Market Report

RA08551

Cytotoxic Drugs Market by Drug Type (Alkylating Agents, Antitumor Antibiotics, Antimetabolites, Plant Alkaloids, and Other Drug Types), Route of Administration (Parenteral and Oral), Application (Breast Cancer, Prostate Cancer, Lung Cancer, Pancreatic Cancer, and Other Applications), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028

RA08551

Pages: 202

Feb 2022

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Cytotoxic Drugs Market

Global Cytotoxic Drugs Market Analysis

The global cytotoxic drugs market is estimated to generate a revenue of $14,885.2 million by 2028, increasing from $13,425.0 million in 2020, at a healthy CAGR of 1.2%.

Market Synopsis

Surging prevalence of cancer to upsurge the cytotoxic drugs market Growth

However, lower product penetration in the low-income regions to restrain the cytotoxic drugs market growth.

According to the regional analysis of the cytotoxic drugs market, the Asia-Pacific market is anticipated to surge at a CAGR of 2.6%, by registering a revenue of $1,760.9 million, during the forecast period.

Cytotoxic Drugs Overview

Cytotoxic drugs also known as antineoplastics, describe a group of drugs that consists of chemicals which are toxic to cells, preventing their growth or replication, and so are used mainly for the treatment of cancer. Cytotoxic drugs (cytotoxic) have multiple applications for disorders such as sclerosis and rheumatoid arthritis.

COVID-19 Impact on Cytotoxic Drugs Market

In response to the Covid-19 pandemic, business sectors namely transportation, petroleum, retail, and tourism industry have been forced to reconsider their business models and policies. Also, global cytotoxic drugs market has witnessed declined growth, throughout the pandemic period mainly because of COVID-induced lockdowns, combined with travel restrictions forced multiple patients to delay their treatment throughout the last 2 years of the outbreak. Moreover, with the rising burden of COVID cases straining hospitals and healthcare professionals, other diseases such as cancer were neglected. All these factors negatively impacted the global cytotoxic drugs market.

On the other hand, key players operating in the cytotoxic drugs market are coming up with novel product launches. For instance, in July 2021, Tevogen Bio, a biotechnology firm specializing in cell and gene therapies in oncology, got approval from U.S. Food and Drug Administration (FDA) for allogeneic COVID-19 specific cytotoxic T-lymphocytes (CTLs), TVGN-489. This drug has demonstrated strong antiviral activity against COVID-19 and is projected to identify and eliminate virus infected cells, enabling the human body to replace them with healthy cells. Such effective product development may further create significant opportunities for the investors, post COVID-19 outbreak.

Surging Prevalence of Cancer to Upsurge the Cytotoxic Drugs Market Growth

Growth of global cytotoxic drugs market is mainly attributed to the massively rising prevalence of cancer across the globe. As per study conducted by the World Health Organization (WHO), the agency of the United Nations (UN) responsible for public health, cancer is a prominent cause of mortality worldwide, accounting for approximately 10+ million deaths in 2020. Therefore, the adoption of cytotoxic chemotherapy drugs namely cytotoxic anticancer drugs and cytotoxic antibiotics is expected to massively increase globally, which may eventually bolster the cytotoxic drugs industry.

To know more about global cytotoxic drugs market drivers, get in touch with our analysts here.

Lower Product Penetration in the Low-income Regions to Restrain the Cytotoxic Drugs Market Growth

However, lack of information about the cytotoxic drugs across the pharmacies in middle or low-income countries may restrain the market growth of global cytotoxic market, throughout the projected period. Further, high cost of cytotoxic drugs may also negatively impact the cytotoxic drugs market, in the coming years.

Significant Expansion of Healthcare Establishments across the Asia-Pacific Region to Create Investment Opportunities

Asia-Pacific economies such as Japan, Australia, India, China, and Singapore have experienced the notable expansion of biotechnology & pharmaceutical companies in the past few years. Furthermore, the massively growing awareness in the Asian consumers about improving the quality of life has also surged. Also, burden of multiple chronic conditions such as lung cancer, breast cancer, and prostate cancer is exponentially rising in the APAC countries. Thereby the consumption and constant growth of cytotoxic/cytostatic drugs in this region has grown, which can create the investment opportunities for global cytotoxic drugs industry, during the analysis period.

To know more about global cytotoxic drugs market opportunities, get in touch with our analysts here.

Cytotoxic Drugs Market
By Drug type

Your browser does not support the canvas element.

Based on drug type, the market has been divided into alkylating agents, antitumor antibiotics, Antimetabolites, plant alkaloids, other drug types of which Antimetabolites sub-segment is anticipated to have largest share and the significant growth, throughout the forecast period. Download PDF Sample Report

Source: Research Dive Analysis

The antimetabolites drugs sub-segment is expected to have the dominating share as well as lucrative growth in the global market and register a revenue of $6,908.1 million by 2028.
Exponentially increasing investments in the field of antimetabolites drugs, mainly owing to its enormous benefits is creating positive impact on the antimetabolites drug’s sub-segment. In addition to this, rise in medical expenditure, rising incidence of breast cancer and lung cancer, and spike in the public awareness regarding chronic cancer diseases are some important factors anticipated to continue to accelerate market growth. Moreover, prominent players of the market are coming up with novel innovations in order to strengthen their presence worldwide. All these elements are further expected to create enormous opportunities, across the globe.  

Cytotoxic Drugs Market
By Route of Administration

Your browser does not support the canvas element.

Based on route of administration, the market has been categorized into oral and Parental. Out of these, the Parental sub-segment is anticipated to garner the maximum revenue in the global market, throughout the analysis period.

Source: Research Dive Analysis

The parental sub-segment of the global cytotoxic drugs market is estimated to grow at the most notable CAGR and surpass $11,273.0 million by 2028, with a rise from $10,076.4 million in 2020. Parental administration of cytotoxic drugs enables for quick entry into the human body's circulation, where it is carried across the body in the blood stream. Also, parental administration of cytotoxic drugs plays important role in shrinking cancer cell or slow down its growth, which may help patient live longer. All these elements are further expected to surge the parental sub-segment, which will eventually fuel the sub-segment’s growth.

Cytotoxic Drugs Market
By Application

Your browser does not support the canvas element.

Based on application, the market has been categorized into Breast Cancer, prostate cancer, lung cancer, pancreatic cancer, and other applications. Out of these, the Breast Cancer sub-segment is anticipated to garner the maximum revenue in the global market, throughout the analysis period.

Source: Research Dive Analysis

The breast cancer sub-segment of the global cytotoxic drugs market is estimated to grow at the most notable CAGR and surpass $5,011.5 million by 2028, with a rise from $4,598.6 million in 2020. Surging prevalence of the disease, combined with invention of novel therapies, is one of the important factors likely to drive the breast cancer sub-segment. As per research conducted by the World Health Organization (WHO), in 2018, breast cancer is the most witnessed cancer, impacting around 2.1 million women each year. All these factors are expected to propel the sub-segment’s growth, during the forecast period.

Global Cytotoxic Drugs Market, Regional Insights:

The cytotoxic drugs market was investigated across North America, Europe, Asia-Pacific, and LAMEA.

Global Cytotoxic Drugs Market, Regional Insights

Source: Research Dive Analysis

The Market for Cytotoxic Drugs in Asia-Pacific to be the Most Lucrative

Asia-Pacific cytotoxic drugs market accounted $1,427.1 million in 2020 and is expected to register a revenue of $1,760.9 million by 2028.
The Asia-Pacific cytotoxic drugs market is expected to be the fastest growing during the forecast period, majorly due to the rise in the prevalence of cancer cases, extensive adoption of advanced healthcare products, and increase in expenditure on healthcare infrastructure. In addition to this, inclusion of cytotoxic drugs in healthcare reimbursements, combined with spike in demand for chemotherapies particularly in Japan, India, and China may drive the Asia-Pacific cytotoxic drugs market, throughout the analysis period.

The North America Cytotoxic Drugs Market to be the Most Dominant

The cytotoxic drugs market for the North America region is anticipated to have a significant share. Cytotoxic drugs market in North America region is competitive and prominent companies operating in the region have adopted numerous strategies to gain largest North America cytotoxic drugs market share. North America cytotoxic drugs market accounted $6,399.7 million in 2020 and is expected to register a revenue of $6,902.3 million by 2028. This growth is mainly driven by the growing incidence of cancer causing diseases. In addition to this, the robust presence of Eli Lilly and Company, AbbVie Inc., and Johnson & Johnson along with their innovative product developments is further expected to significantly impact the global cytotoxic drugs market, in the forecast period.

Competitive Scenario in the Global Cytotoxic Drugs Market

Treatment type launches and mergers & acquisitions are common strategies followed by major market players.

Competitive Scenario in the Global Cytotoxic Drugs Market

Source: Research Dive Analysis

Some of the leading cytotoxic drugs market players are Pfizer Inc., AbbVie Inc., Johnson & Johnson, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Merck & Co. Inc., Sanofi, Novartis AG, and Eli Lilly and Company.

Porter’s Five Forces Analysis for the Global Cytotoxic Drugs Market:

  • Bargaining Power of Suppliers: The suppliers operating in the global cytotoxic agent/drugs are high in number and are much larger and more globalized. So, there will be less threat from the supplier.
    Thus, the bargaining power of the suppliers is low.    
  • Bargaining Power of Buyers: Buyers demand effective cytotoxic drugs at lower cost. This has increased the pressure on the multiple drug manufacturers to offer the medications in a cost-effective way. Thus, many suppliers have started offering best yet cost–effective cytotoxic drugs. This gives the buyers the option to freely choose cytotoxic drugs that best fit their preference.
    Thus, the bargaining power of the buyers is high.
  • Threat of New Entrants: The companies entering the global cytotoxic drugs market are adopting technological innovations to attract customers. Also, these companies are implementing various effective strategies and there is government support in some countries.
    Thus, threat of the new entrants is high.
  • Threat of Substitutes: There is no alternative treatment type available. 
    Thus, the threat of substitutes is low.
  • Competitive Rivalry in the Market: The competitive rivalry among the industry leaders is rather intense, especially between the global players including Bristol Myers Squibb (BMS), Gilead Sciences, Inc., and AbbVie. These companies are launching their value-added products such as enzalutamide cytotoxic and dutasteride cytotoxic in the international market and strengthening the footprint worldwide.
    Therefore, the competitive rivalry in the market is high.

Aspect

Particulars

  Historical Market Estimations

  2019-2020

  Base Year for Market Estimation

  2020

  Forecast timeline for Market Projection

  2021-2028

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Drug Type

  • Alkylating Agents
  • Antitumor Antibiotics
  • Antimetabolites
  • Plant Alkaloids
  • Other Drug Types

  Segmentation by Route of Administration

  • Oral
  • Parental

  Segmentation by Application

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Other Applications

  Key Countries Covered

 U.S., Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, South Korea, Rest of Asia-Pacific, Brazil, Saudi Arabia, United Arab Emirates, Rest of LAMEA

  Key Companies Profiled

  • Pfizer Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb
  • Merck & Co. Inc.
  • Sanofi
  • Novartis AG
  • Eli Lilly and Company

Frequently Asked Questions
 

A. Cytotoxic drugs also known as antineoplastics describe a group of drugs that consists of chemicals which are toxic to cells, preventing their growth or replication, and so are used mainly for the treatment of cancer.

A. The global cytotoxic drugs market size was over $13,425.0 million in 2020 and is projected to reach $14,885.2 million by 2028.

A. F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., and Sanofi are some of the key players in the global cytotoxic drugs Market.

A. All cytotoxic drugs used clinically are prepared within the pharmacy department.

A. The Asia-Pacific region possesses great investment opportunities for the investors to witness the most promising growth in the future.

A. Asia-Pacific cytotoxic drugs market is anticipated to grow at 2.6% CAGR during the forecast period.

A. Capacity expansion and treatment type development, along with joint ventures are the key strategies opted by the operating companies in this market.

A. Novartis AG, Bristol Myers Squibb (BMS), and Gilead Sciences, Inc. are investing more on R&D activities for developing new treatment types and technologies.

A. Cytotoxic anti-cancer drugs proved to be highly cytotoxic agents to normal cells like lymphocyte cells.

A. COVID-19 outbreak has negatively affected the cytotoxic drugs market.

A. Geographically, North America is the largest segment in the in the global cytotoxic drugs market.

A. Presence of strong pipeline, growing prevalence of cancer, availability of novel drugs, and supportive government policies for disease awareness are some of the major growth catalysts for the global cytotoxic drugs market.

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

1.5.Data sources

1.5.1.Primary
1.5.2.Secondary

2.Executive Summary

2.1.360° summary
2.2.By drug type trends
2.3.By route of administration trends
2.4.By application trends

3.Market overview

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five forces analysis

3.3.1.Bargaining power of consumers
3.3.2.Bargaining power of suppliers
3.3.3.Threat of new entrants
3.3.4.Threat of substitutes
3.3.5.Competitive rivalry in the market

3.4.Market dynamics

3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities

3.5.Technology landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Pricing overview

3.8.1.by drug type
3.8.2.by route of administration
3.8.3.by application

3.9.Market value chain analysis

3.9.1.Stress point analysis
3.9.2.Raw material analysis
3.9.3.Manufacturing process
3.9.4.Distribution channel analysis
3.9.5.Operating vendors

3.9.5.1.Raw material suppliers
3.9.5.2.Product manufacturers
3.9.5.3.Product distributors

3.10.Strategic overview

4.Cytotoxic Drugs Market, by Drug Type

4.1.Alkylating agents

4.1.1.Key market trends, growth factors, and opportunities
4.1.2.Market size and forecast, by region, 2020-2028
4.1.3.Market share analysis, by country, 2020 & 2028

4.2.Antitumor antibiotics

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region, 2020-2028
4.2.3.Market share analysis, by country, 2020 & 2028

4.3.Antimetabolites

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region, 2020-2028
4.3.3.Market share analysis, by country, 2020 & 2028

4.4.Plant Alkaloids

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region, 2020-2028
4.4.3.Market share analysis, by country, 2020 & 2028

4.5.Other Drug Types

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region, 2020-2028
4.5.3.Market share analysis, by country, 2020 & 2028

5.Cytotoxic Drugs Market, by Route of Administration 

5.1.Parenteral

5.1.1.Key market trends, growth factors, and opportunities
5.1.2.Market size and forecast, by region, 2020-2028
5.1.3.Market share analysis, by country, 2020 & 2028

5.2.Oral

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region, 2020-2028
5.2.3.Market share analysis, by country, 2020 & 2028

6.Cytotoxic Drugs Market, by Application

6.1.Breast Cancer

6.1.1.Key market trends, growth factors, and opportunities
6.1.2.Market size and forecast, by region, 2020-2028
6.1.3.Market share analysis, by country, 2020 & 2028

6.2.Prostate Cancer

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region, 2020-2028
6.2.3.Market share analysis, by country, 2020 & 2028

6.3.Lung Cancer

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region, 2020-2028
6.3.3.Market share analysis, by country, 2020 & 2028

6.4.Pancreatic Cancer

6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region, 2020-2028
6.4.3.Market share analysis, by country, 2020 & 2028

6.5.Other Applications

6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region, 2020-2028
6.5.3.Market share analysis, by country, 2020 & 2028

7.Cytotoxic Drugs Market, by Region

7.1.North America

7.1.1.Key market trends, growth factors, and opportunities
7.1.2.Market size and forecast, by drug type, 2020-2028
7.1.3.Market size and forecast, by route of administration, 2020-2028
7.1.4.Market size and forecast, by application, 2020-2028
7.1.5.Market size and forecast, by country, 2020-2028

7.1.6.U.S.

7.1.6.1.Market size and forecast, by drug type, 2020-2028
7.1.6.2.Market size and forecast, by route of administration, 2020-2028
7.1.6.3.Market size and forecast, by application, 2020-2028

7.1.7.Canada

7.1.7.1.Market size and forecast, by drug type, 2020-2028
7.1.7.2.Market size and forecast, by route of administration, 2020-2028
7.1.7.3.Market size and forecast, by application, 2020-2028

7.1.8.Mexico

7.1.8.1.Market size and forecast, by drug type, 2020-2028
7.1.8.2.Market size and forecast, by route of administration, 2020-2028
7.1.8.3.Market size and forecast, by application, 2020-2028

7.2.Europe

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by drug type, 2020-2028
7.2.3.Market size and forecast, by route of administration, 2020-2028
7.2.4.Market size and forecast, by application, 2020-2028
7.2.5.Market size and forecast, by country, 2020-2028

7.2.6.Germany 

7.2.6.1.Market size and forecast, by drug type, 2020-2028
7.2.6.2.Market size and forecast, by route of administration, 2020-2028
7.2.6.3.Market size and forecast, by application, 2020-2028

7.2.7.UK

7.2.7.1.Market size and forecast, by drug type, 2020-2028
7.2.7.2.Market size and forecast, by route of administration, 2020-2028
7.2.7.3.Market size and forecast, by application, 2020-2028

7.2.8.France

7.2.8.1.Market size and forecast, by drug type, 2020-2028
7.2.8.2.Market size and forecast, by route of administration, 2020-2028
7.2.8.3.Market size and forecast, by application, 2020-2028

7.2.9.Spain

7.2.9.1.Market size and forecast, by drug type, 2020-2028
7.2.9.2.Market size and forecast, by route of administration, 2020-2028
7.2.9.3.Market size and forecast, by application, 2020-2028

7.2.10.Italy 

7.2.10.1.Market size and forecast, by drug type, 2020-2028
7.2.10.2.Market size and forecast, by route of administration, 2020-2028
7.2.10.3.Market size and forecast, by application, 2020-2028

7.2.11.Rest of Europe

7.2.11.1.Market size and forecast, by drug type, 2020-2028
7.2.11.2.Market size and forecast, by route of administration, 2020-2028
7.2.11.3.Market size and forecast, by application, 2020-2028

7.3.Asia Pacific

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by drug type, 2020-2028
7.3.3.Market size and forecast, by route of administration, 2020-2028
7.3.4.Market size and forecast, by application, 2020-2028
7.3.5.Market size and forecast, by country, 2020-2028

7.3.6.China

7.3.6.1.Market size and forecast, by drug type, 2020-2028
7.3.6.2.Market size and forecast, by route of administration, 2020-2028
7.3.6.3.Market size and forecast, by application, 2020-2028

7.3.7.India 

7.3.7.1.Market size and forecast, by drug type, 2020-2028
7.3.7.2.Market size and forecast, by route of administration, 2020-2028
7.3.7.3.Market size and forecast, by application, 2020-2028

7.3.8.Japan

7.3.8.1.Market size and forecast, by drug type, 2020-2028
7.3.8.2.Market size and forecast, by route of administration, 2020-2028
7.3.8.3.Market size and forecast, by application, 2020-2028

7.3.9.South Korea

7.3.9.1.Market size and forecast, by drug type, 2020-2028
7.3.9.2.Market size and forecast, by route of administration, 2020-2028
7.3.9.3.Market size and forecast, by application, 2020-2028

7.3.10.Australia

7.3.10.1.Market size and forecast, by drug type, 2020-2028
7.3.10.2.Market size and forecast, by route of administration, 2020-2028
7.3.10.3.Market size and forecast, by application, 2020-2028

7.3.11.Rest of Asia Pacific

7.3.11.1.Market size and forecast, by drug type, 2020-2028
7.3.11.2.Market size and forecast, by route of administration, 2020-2028
7.3.11.3.Market size and forecast, by application, 2020-2028

7.4.LAMEA

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by drug type, 2020-2028
7.4.3.Market size and forecast, by route of administration, 2020-2028
7.4.4.Market size and forecast, by application, 2020-2028
7.4.5.Market size and forecast, by country, 2020-2028

7.4.6.Latin America  

7.4.6.1.Market size and forecast, by drug type, 2020-2028
7.4.6.2.Market size and forecast, by route of administration, 2020-2028
7.4.6.3.Market size and forecast, by application, 2020-2028

7.4.7.Middle East 

7.4.7.1.Market size and forecast, by drug type, 2020-2028
7.4.7.2.Market size and forecast, by route of administration, 2020-2028
7.4.7.3.Market size and forecast, by application, 2020-2028

7.4.8.Africa

7.4.8.1.Market size and forecast, by drug type, 2020-2028
7.4.8.2.Market size and forecast, by route of administration, 2020-2028
7.4.8.3.Market size and forecast, by application, 2020-2028

8.Company profiles

8.1.Pfizer Inc.

8.1.1.Company overview
8.1.2.Operating business segments
8.1.3.Product portfolio
8.1.4.Financial performance
8.1.5.Key strategy moves and development

8.2.AbbVie Inc.

8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Financial performance
8.2.5.Key strategy moves and development

8.3.Johnson & Johnson

8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio
8.3.4.Financial performance
8.3.5.Key strategy moves and development

8.4.GlaxoSmithKline plc.

8.4.1.Company overview
8.4.2.Operating business segments
8.4.3.Product portfolio
8.4.4.Financial performance
8.4.5.Key strategy moves and development

8.5.F. Hoffmann-La Roche AG

8.5.1.Company overview
8.5.2.Operating business segments
8.5.3.Product portfolio
8.5.4.Financial performance
8.5.5.Key strategy moves and development

8.6.Bristol-Myers Squibb

8.6.1.Company overview
8.6.2.Operating business segments
8.6.3.Product portfolio
8.6.4.Financial performance
8.6.5.Key strategy moves and development

8.7.Merck & Co. Inc.

8.7.1.Company overview
8.7.2.Operating business segments
8.7.3.Product portfolio
8.7.4.Financial performance
8.7.5.Key strategy moves and development

8.8.Sanofi

8.8.1.Company overview
8.8.2.Operating business segments
8.8.3.Product portfolio
8.8.4.Financial performance
8.8.5.Key strategy moves and development

8.9.Novartis AG

8.9.1.Company overview
8.9.2.Operating business segments
8.9.3.Product portfolio
8.9.4.Financial performance
8.9.5.Key strategy moves and development

8.10.Eli Lilly and Company

8.10.1.Company overview
8.10.2.Operating business segments
8.10.3.Product portfolio
8.10.4.Financial performance
8.10.5.Key strategy moves and development

Cytotoxic drugs consist of chemicals that effectively work on fast-growing cells like cancer cells, bone marrow, hair follicles, cells in the intestines, etc. These fast-growing cells are at different positions in the division process, it is not possible for cytotoxic drugs to kill all these toxic cells at once. And so, many chemotherapy regimens include numerous repetitive drugs and treatment cycles for the whole procedure. In addition, these cytotoxic drugs have other applications as well for disorders like rheumatoid arthritis, sclerosis, etc.

Forecast Analysis

The growth of the global cytotoxic drugs market is primarily attributed to the dominant prevalence of cancer across the world. Several healthcare establishments are opting for cytotoxic chemotherapy drugs and antibiotics, thus boosting the market growth. In addition, significant expansion of prominent biotechnology and pharmaceutical companies in the Asia-Pacific region is anticipated to further accelerate the market growth during the forecast period. However, the lack of information about cytotoxic drugs in low-income countries is the major factor projected to impede the growth of the global cytotoxic drugs market.

Regionally, the cytotoxic drugs market in the North America region is predicted to hold a dominant market share and garner a revenue of $6,902.3 million during the analysis timeframe. The growing prevalence of cancer and other chronic diseases breast cancer and prostate cancer is the main factor to boost the market growth in the region. In addition, existence of some prominent market players and biotechnology firms and their innovative product advancements is also expected to propel the cytotoxic drugs market development in the North America region by 2028.

According to the report published by Research Dive, the global cytotoxic drugs market is estimated to garner a revenue of $14,885.2 million and grow at 1.2% CAGR in the 2021–2028 timeframe. Some prominent market players include AbbVie Inc., Sanofi, Johnson & Johnson, Novartis AG, GlaxoSmithKline PLC, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Pfizer Inc., and many others.

Covid-19 Impact on the Market

The onset of the Covid-19 pandemic has had an adverse effect on several business and have forced industries to reconsider their operational model. The global cytotoxic drugs market is no exception to this negative impact. Government-imposed strict lockdowns along with travel restrictions compelled many patients to delay their treatments, thus declining the demand for cytotoxic drugs. Moreover, amid the rising corona virus patients in hospitals, other diseases and their treatments were sidelined. However, considering new innovative product launches by market players, the market might revive its growth rate post the pandemic stress.

Key Market Developments

The significant companies operating in the industry are adopting numerous growth strategies & business tactics, such as partnerships, collaborations, mergers & acquisitions, and launches to maintain a robust position in the overall cytotoxic drugs market, thus helping the sleepwear market to flourish. For instance:

In January 2022, Eisana Corporation, a new cancer treatment and medical device company, announced its collaboration with Cortex Design, a leading engineering design firm for medical and life sciences, to produce the former’s first product. Eisana’s new cancer treatment device is tech-enabled, affordable, and effectively prevents chemotherapy-induced peripheral neuropathy (CIPN).

In August 2021, Pfizer Inc., an Amerian pharmaceutical and biotechnology company, announced its acquisition of Trillium Therapeutics Inc., a clinical stage immune-oncology company, to expand its drug portfolio with the help of the latter’s two lead molecules. Trillium Therapeutics has decided to provide its two early clinical stage lead molecules that are designed to fight blood cancers.

In December 2021, Becton, Dickinson, and Company (BDC), an American multinational medical technology company, announced its acquisition of Venclose, a medical technology organization, to include the latter’s RF ablation technology that effectively treats chronic venous insufficiency (CVI), in its product portfolio.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed